Research area
Cancer Immunotherapy
Immune-directed cancer treatments, including therapeutic vaccines and oncolytic approaches. Engineered cell products belong under Cell & Gene Therapy.
-
Evidence date ·How might virus-shaped particles guide a cancer vaccine’s immune signal to lymph nodes?
Review or Meta-AnalysisA review discusses dendritic-cell-mediated targeting and lymphatic drainage as distinct strategies for virus-like particles. Production and immune variability remain hurdles.
-
Evidence date ·Why cancer vaccine exosomes need more than the right cargo
Review or Meta-AnalysisA March 2026 review compares ways to load tumor antigens into exosomes and direct the vesicles toward immune cells. Early human studies show limited, varied responses.
-
Evidence date ·How lingering growth-arrested cells reshape lung cancer’s immune surroundings
Review or Meta-AnalysisA January 2026 review examines how senescent cells affect immunity in lung cancer and why proposed ways to clear them or limit their signals need clinical testing.
-
Evidence date ·What a melanoma vaccine trial can and cannot show
Review or Meta-AnalysisIn a melanoma trial, adding a personalized mRNA vaccine to pembrolizumab improved recurrence-free survival. The vaccine alone was not tested.
-
Evidence date ·A tumor biopsy gets a control phase and a drug test in the same well
Clinical TrialResearchers tested living tumor fragments from biopsies by measuring immune activity before and after checkpoint drugs. The approach still needs clinical validation.
-
Evidence date ·Can IgM’s ten binding sites lead to a solid tumor treatment?
Review or Meta-AnalysisA 2025 review explains how IgM may bind tumor cells with sparse or unevenly expressed markers. It surveys early candidates; patient benefit remains unproven.
-
Evidence date ·Why are secretions from cells that stopped dividing a difficult cancer target?
Review or Meta-AnalysisThe review traces how senescent-cell secretions recruit immune defenders or support tumor escape, and why proposed combinations still depend on tumor context and clinical testing.
-
Evidence date ·How immunotherapy designs widen cancer recognition and try to limit mistaken attacks
Review or Meta-AnalysisA June 2025 review compares ways to recognize more tumor markers with designs meant to protect healthy tissue, and shows why clinical tradeoffs remain unsettled.
-
Evidence date ·When cancer treatment releases the immune system’s brakes, the setting matters
Review or Meta-AnalysisThe review explains how PD-1 and CTLA-4 restrain T cells, compares treatment prospects across cancers, and weighs combination strategies against immune-related side effects.
-
Evidence date ·Why are researchers looking beyond one immune pathway in head and neck cancer?
Review or Meta-AnalysisA 2025 review surveys four immune targets beyond PD-1/PD-L1 in head and neck cancer. It does not establish patient benefit or the safety of combinations.